FDA Recalls Dihydroergotamine Mesylate Injection for Temperature Abuse
McKesson Medical-Surgical is recalling Dihydroergotamine Mesylate Injection (NDC 0574-0850-10) due to temperature deviations during manufacturing that may affect product quality. The drug was distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for manufacturing deviations (temperature abuse) affecting product quality. No illnesses or injuries have been reported, consistent with a voluntary precautionary recall.
Plain-English summary
McKesson Medical-Surgical Inc. is recalling Dihydroergotamine Mesylate, Injection, USP, 1mg/mL, packaged in boxes of 5 x 1 mL ampules (NDC 0574-0850-10), manufactured for Perrigo, Minneapolis, MN. This is a prescription pharmaceutical injection.
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations involving temperature abuse during the manufacturing process. These deviations may affect product quality.
The affected product was distributed nationwide throughout the United States. McKesson Medical-Surgical Inc. was unable to identify specific lot numbers received by individual customers and instead sent notifications directly with shipping date information relevant to each customer's orders.
Customers who received this product should contact their healthcare provider or pharmacy for guidance.
The recalled product
- Product
- Dihydroergotamine Mesylate, Injection, USP, 1mg/mL, packaged in box of 5 x 1 mL ampules, Rx only, Manufactured for: Perrigo, Minneapolis, MN, NDC 0574-0850-10
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug
- Hazard
- temperature-abuse
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27